Generated by AI
Immuron Ltd. Sponsored ADR is the U.S.-listed depositary receipt for Immuron Limited, an Australian biopharmaceutical company focused on developing and commercializing oral polyclonal antibody products. Immuron’s current portfolio centers on products and programs designed for gastrointestinal and infectious disease applications, including Travelan, an over-the-counter product used to help reduce the risk of traveler’s diarrhea, and Protectyn, an immune supplement marketed for digestive health support. The company also maintains a research and development pipeline built around targeted antibody technologies and clinical-stage candidates for enteric and other gut-mediated conditions. Through its commercial products and clinical programs, Immuron participates in both consumer health and specialty biopharmaceutical markets, serving as a niche player in microbiome-linked and immune-focused therapies.
Website62 Lygon Street
Carlton, VIC, 3053
Australia
The latest articles about IMRN.
MELBOURNE, Australia, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) today announced that it has engaged LifeSci Capital to serve as its exclusive financial advisor to assist in evaluation of strategic initiatives aimed at maximising shareholder value. Strategic initiatives under consideration may include, but are not limited to mergers, acquisitions, licensing, or other strategic transactions. There can be no assurance that the strategic process will result in any tr
Detailed price information for Immuron Ltd ADR (IMRN-Q) from The Globe and Mail including charting and trades.
Summary of Sep 8's posts. Generated by AI.
Summary of Sep 4's posts. Generated by AI.
Summary of Sep 8's posts. Generated by AI.
Investors talking about IMRN also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.